Johnson & Johnson (JNJ)

FairStock Score: 75/100 — HIGH CONVICTION

Key Financials

Strengths

• Fortress balance sheet with $16.6B annual free cash flow and 20.83% net margins demonstrate operational excellence
• Diversified healthcare portfolio across innovative medicines and MedTech reduces single-product risk
• Exceptional 35.03% ROE shows efficient capital deployment and pricing power
• Low beta of 0.33 provides downside protection during market stress
• Strong dividend history and cash generation support shareholder returns

Concerns

• Valuation disconnect: P/E of 21.32 versus Graham Number of $40.19 offers negative margin of safety of -503.61%
• Piotroski F-Score of only 3/9 indicates deteriorating financial strength and quality trends
• Elevated EV/EBITDA of 85.22 leaves minimal room for disappointment or growth shortfalls
• Patent cliff risks in Innovative Medicine segment and regulatory pressures on pharmaceutical pricing

AI Analysis

Johnson & Johnson presents a classic defensive healthcare compounder, but current valuation demands scrutiny. At $242.59 with a P/E of 21.32, we're paying a considerable premium to the Graham Number of $40.19—a negative margin of safety exceeding 500%. This is neither Mr. Graham nor I would typically accept. However, the business quality is undeniable: a 20.83% net margin in Q4 2025, $16.6B in free cash flow, and an exceptional 35.03% ROE demonstrate pricing power and operational excellence across pharmaceuticals and medical devices. The low beta of 0.33 reflects defensive characteristics. Yet here's my concern: the Piotroski F-Score of 3/9 is worrisome, suggesting deteriorating financial strength. The EV/EBITDA multiple of 85.22 is extraordinarily high, and the 0.9% FCF yield leaves minimal room for error. A debt-to-equity of 0.60 is manageable but requires steady cash generation. The company's dual segments—Innovative Medicine and MedTech—provide diversification, but pharmaceutical patent cliffs and regulatory pressures are real headwinds. I respect JNJ's moat and management, but I cannot reconcile this valuation with a margin of safety. We're paying for perfection in a business facing structural challenges. At perhaps $150-160, this becomes interesting; at $242, it's priced for flawless execution.

Bull Case

JNJ's fortress cash generation of $16.6B annually, combined with a resilient healthcare moat and consistent 20%+ margins, supports long-term compounding. Patent portfolio strength in oncology and immunology, coupled with strategic MedTech assets, positions the company for sustained dividend growth and capital appreciation over 10+ years.

Bear Case

The stock is priced for perfection at 85x EV/EBITDA with deteriorating F-Score fundamentals. Any stumble in drug launches, regulatory setbacks, or margin compression could trigger significant multiple contraction, particularly given the weak 0.9% FCF yield provides no valuation cushion.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer